ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.
Nishioka
C
C
Ikezoe
T
T
Takeshita
A
A
Yang
J
J
Tasaka
T
T
Yang
Y
Y
Kuwayama
Y
Y
Komatsu
N
N
Togitani
K
K
Koeffler
H P
HP
Taguchi
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008875:Middle Aged; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D010880:Piperidines / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D014407:Tumor Cells, Cultured
C517975:AZD 6244; D001562:Benzimidazoles; D010880:Piperidines; D011799:Quinazolines; D020929:Mitogen-Activated Protein Kinase Kinases; C452423:vandetanib